aTyr Pharma to Present at Upcoming Investor Conferences in November
12 nov. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
10 nov. 2021 16h00 HE
|
aTyr Pharma, Inc.
Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2...
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
09 nov. 2021 08h05 HE
|
aTyr Pharma, Inc.
Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data...
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
03 nov. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Participate in Piper Sandler Investor Lung Day
11 oct. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
06 oct. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
01 oct. 2021 08h01 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
20 sept. 2021 16h07 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
16 sept. 2021 16h01 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock
16 sept. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...